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Drug Matrix cell A1: Interventions; Reducing harm
S  The study which (seemed to have) val idated needle exchange in the UK (1989). Publ ished journal  article reported “smal l  but
encouraging” extra reductions  in the HIV risk behaviour of attendees  at pi lot exchanges  in England and Scotland versus  a
comparison group, legitimating nationwide expansion. But an Effectiveness  Bank cri tique (2004) reminds  us  of an unpubl icised
comparison, which was not encouraging at a l l . For discuss ion cl ick here and scrol l  down to highl ighted heading in bi te’s  Issues
section.
S  Methadone maintenance protects  against HIV infection (1993). Over the 18-month fol low-up, 22% of US injectors  who had not
been on methadone became HIV pos itive but just 3.5% who had remained in methadone maintenance, a  “striking” di fference
attributed partly to their reduced injecting and sharing of injecting equipment. For related discuss ion cl ick here and scrol l  down to
highl ighted heading in bi te’s  Issues section.
S  Methadone treatment saved l ives  in Sweden (1990). Restrictions  on methadone maintenance in Sweden enabled i ts  value to be
convincingly demonstrated; when detoxi fication and drug-free treatment were the al ternatives , deaths  were about eight times
higher. Reviewed with other Swedish studies  in The Swedish experience (2000) on p. 6 of l inked PDF fi le. See later confi rmatory
studies  (1 2) from Sweden, and below s imi lar studies  from Norway. For discuss ion cl ick here and scrol l  down to highl ighted
heading in bi te’s  Highlighted study section.
K  Expand needle exchange and opioid substi tute prescribing to contain hepati tis  C (2011). Pooled UK data showed that being and
staying in methadone maintenance and al l ied treatments  plus  adequate access  to fresh injecting equipment has  prevented many
hepati tis  C infections. Extrapolating from this  data indicated (2012) that to make further substantia l  progress  these interventions
must reach not hal f of UK injectors , but at least 8 in 10. Some of same authors  have col lated (2014) studies  contradicting previous
conclus ions  that opioid substi tute prescribing does  not prevent spread of hepati tis  C. For discuss ion cl ick here and scrol l  down to
highl ighted heading in bi te’s  Issues section.
K  US randomised tria l  confi rms that methadone maintenance prevents  infection risk behaviours  (2000). Proving methadone
maintenance reduces  risk of infection has  been hampered by the near absence of randomised tria ls , hence the importance of this
US study contrasting continuing maintenance with detoxi fication. Despite being compensated for by more intens ive psychosocial
support, when methadone was withdrawn gaps  in infection risk behaviour and i l l i ci t opioid use opened up favouring the
maintenance patients . For discuss ion cl ick here and scrol l  down to highl ighted heading in bi te’s  Highlighted study section.
K  Longer on methadone means longer l ives  for UK heroin patients  treated by GPs  (2010). GP records  suggest opiate users  are less
l ikely to die prematurely i f substi tute prescribing is  made avai lable, and that the longer they are in treatment, the greater the l i fe
expectancy dividend. This  data led to the estimate (2011) that shortening an average nine months  of treatment to s ix would cause
10% more deaths  whi le extending i t to 12 would cause 5% fewer. Simi lar study of specia l is t services  below. For related discuss ion
cl ick here and scrol l  down to highl ighted heading in bi te’s  Highlighted study section.
K  Engl ish study finds  staying in specia l is t substi tute prescribing treatment saves  l ives  (2015). Results  suggest that to save the l ives
of people dependent on heroin or s imi lar drugs, they should be engaged and retained in substi tute prescribing programmes l ike
methadone maintenance. Shortly after leaving res identia l/inpatient care was the highest-risk period. Simi lar study of primary care
patients  above and below of opiate users  in general  whether in treatment or not. For related discuss ion cl ick here and scrol l  down
to highl ighted heading in bi te’s  Highlighted study section.
K  Without treatment there might have been 70% more opioid overdose deaths  in England (2015). Estimates  that across  the entire
population of problem opiate users  in England, between 2008 and 2011 addiction treatment (mainly substi tute prescribing)
reduced total  opioid-related overdose deaths  from what would have been 6372 to 3731. Simi lar study but confined to treatment
patients  above. For related discuss ion cl ick here and scrol l  down to highl ighted heading in bi te’s  Highlighted study section.
K  Restricted access  in Norway exposes  substi tute prescribing’s  l i fesaving potentia l  (2008). During their long wait for a  s lot in
Norway’s  substi tute prescribing programme, five times as  many opiate-dependent appl icants  died due to overdose as  did patients
in treatment. Simi lar findings  (2013) in respect of drug-related phys ical  complaints . Message is  that services  should strive to
retain ‘problem patients ’ in treatment. Simi lar Swedish studies  above. For discuss ion cl ick here and scrol l  down to highl ighted
heading in bi te’s  Highlighted study section.
K  Treatment offers  shelter from overdose risk (2008) Reports  on a large Ita l ian study (2007) which highl ighted the protection
against overdose deaths  afforded by being in treatment, and the danger of leaving with reduced tolerance to opiate drugs  but sti l l
vulnerable to relapse.
K  Training drug users  to administer overdose-revers ing medication (2008). Fi rst large UK fol low-up study confi rmed the feas ibi l i ty
and to a  degree the des ired impacts  of overdose prevention training featuring the opiate-blocking drug naloxone. However, often
naloxone was not used (2009) because drug users  were reluctant to carry around the pre-loaded syringes, and naloxone training
‘cascaded’ (2011) to other cl inicians  and patients  at a  snai l ’s  pace. For related discuss ion cl ick here and scrol l  down to
highl ighted heading in bi te’s  Issues section.
K  Scotland’s  pioneering naloxone programme saved l ives  of released prisoners  (2016). In 2011 Scotland became the fi rst country
to fund a national  pol icy of distributing the opiate-blocker naloxone to prevent opioid overdose deaths. According to this
evaluation i t did prevent deaths  where this  was  most l ikely to be seen – shortly after release from prison. For discuss ion cl ick here
and scrol l  down to highl ighted heading in bi te’s  Issues section.
K  Welsh pi lot study leads  to national  naloxone programme (2012). The evaluation which led to the Welsh national  programme to
distribute naloxone to opiate users  and their associates  to curb ris ing opiate overdose deaths. For related discuss ion cl ick here
and scrol l  down to highl ighted heading in bi te’s  Issues section.
R  Overview of drug-related harms to health and how to reduce them (2005). Reviewed expertly and from a UK perspective,
panoramic view of international  research on the impacts  of needle exchange, prescribing and psychosocial  interventions  on harms
including infections  and overdose. Focus  is  on the conclus ions  reached by United Nations  agencies . For discuss ion cl ick here and
scrol l  down to highl ighted heading in bi te’s  Where should I start? section.
R  Opiate substi tute treatment cuts  HIV infection rate (2005). Pooled results  from nine studies  from across  the world offer “strong
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evidence” that opiate substi tution treatment has  been associated with a  54% reduction in the risk of HIV infection. For related
discuss ion cl ick here and scrol l  down to highl ighted heading in bi te’s  Issues section.
R  Psychosocial  programmes not the way to reduce HIV risk (Cochrane review, 2010). Found no evidence that multiple
training/information sess ions  were any more effective than minimal  educational  interventions  at preventing behaviour which risks
HIV infection among injectors  or cocaine users . Findings  s imi lar (2012) in respect of hepati tis  C.
R  Preventing drug-related disease spread in prisons  (2009). Free source at time of writing. Having been in prison has  repeatedly
been associated with increased risk of infection. Review concludes  that needle and syringe programmes and opioid substi tute
prescribing reduce infection risk behaviours  in prisons  without adversely affecting the health of staff or prisoners . Role of
substi tute prescribing confi rmed by another review (2010).
R  WHO finds  “compel l ing evidence” for needle and syringe programmes’ anti -HIV impact (World Health Organization, 2004). But
the WHO-commiss ioned experts  a lso concluded whi le necessary these programmes are not sufficient; a lso needed are education,
treatment (especial ly substi tute prescribing) and community development. Findings  a lso publ ished in two journal  articles  (1 2).
For related discuss ion cl ick here and scrol l  down to highl ighted heading in bi te’s  Issues section.
R  Needle exchange faces  the chal lenge of hepati tis  C (2003 and 2004). Four-part series  from Drug and Alcohol  Findings  documents
the di fficulty needle exchanges  have had in control l ing spread of hepati tis  C and identi fies  promis ing practice ingredients . For
related discuss ion cl ick here and scrol l  down to highl ighted heading in bi te’s  Issues section.
R  Needle exchanges  wi l l  prevent more infections  by switching to low dead space syringes/needles  (2013). Simulation model
suggests  that switching injectors  from high to low dead space syringes/needles  which retain much less  fluid can prevent or reverse
injection-related HIV epidemics . Engl ish study (2017) found low dead space equipment acceptable to injectors  but may need to be
introduced gradual ly. Laboratory study (2017) suggests  that to prevent spread of hepati tis  C, exchanges  should focus  on needles
and syringes  rather than other injecting equipment.
R  Feas ibi l i ty and effects  of naloxone distribution programmes (2014). Free source at time of writing. Because l ives  are at stake no
randomised tria ls  were found by this  systematic review, but across  19 studies  naloxone was administered 1949 times, general ly
with a  100% survival  rate. For related discuss ion cl ick here and scrol l  down to highl ighted heading in bi te’s  Issues section.
R  Anti -overdose strategies  (Scottish Government, 2008). Wide-ranging review including responding appropriately in an emergency,
naloxone, ambulance protocols , local  col laborations, and information campaigns. Includes  fresh data from surveys  and
interviews in Scotland with drug users  and their fami l ies  and pol ice and emergency services .
R  Safe consumption rooms reduce risk of drug-related harm and promote treatment entry (European Monitoring Centre for Drugs
and Drug Addiction [EMCDDA], 2017). European Union’s  drug misuse centre reviews three decades  of experience and research from
Europe and elsewhere on centres  where i l l i ci t drugs  can be used under the supervis ion of tra ined staff, faci l i ties  increas ingly being
considered in the UK.
G  NICE endorses  needle and syringe programmes (National  Insti tute for Health and Care Excel lence [NICE], 2014). UK’s  officia l
health advisory body finds  needle exchange “an effective way to reduce many of the risks  associated with injecting drugs” though
there was “insufficient evidence” in relation to hepati tis  C. Recommends expansion so every injector has  more steri le equipment
than they need for every injection. See also related qual i ty standards  (NICE, 2012). For related discuss ion cl ick here and scrol l
down to highl ighted heading in bi te’s  Issues section.
G  WHO “strongly recommends” needle exchange and maintenance prescribing to combat HIV (World Health Organization, 2014).
Consol idates  WHO guidance on HIV prevention, diagnosis , treatment and care for key populations  including prisoners  and people
who inject drugs. Strongly advocates  universal  access  of injectors  to needle exchange and of dependent opioid users  to indefini te,
high dose methadone and buprenorphine maintenance.
G  UK government’s  advisers  cal l  for investment in substi tute prescribing to reduce overdose deaths  ([UK] Advisory Counci l  on the
Misuse of Drugs, 2016). UK’s  officia l  drugs  pol icy advisory body concludes  that an ageing population of heroin users  in poor
health has  contributed to recent increases  in drug-related deaths, and that to hold down the increases  government must maintain
investment in substi tute prescribing. For related discuss ion cl ick here and scrol l  down to highl ighted heading in bi te’s  Highlighted
study section.
G  WHO says  better access  to naloxone wi l l  save l ives  (World Health Organization, 2014). WHO judges  that “Increased access  to
naloxone for people l ikely to witness  an overdose could s igni ficantly reduce the high numbers  of opioid overdose deaths” and
makes corresponding recommendations, but a lso stresses  that naloxone provis ion “does  not address  the underlying causes  of
opioid overdose”. For discuss ion cl ick here and scrol l  down to highl ighted heading in bi te’s  Where should I start? section, or here
for related discuss ion in Issues section.
G  Increase avai labi l i ty of overdose-revers ing drug ([UK] Advisory Counci l  on the Misuse of Drugs, 2012). UK’s  officia l  drugs  pol icy
advisory body recommends that the opiate-blocker naloxone and related training be made more widely and eas i ly avai lable to
drug users  and their associates  to prevent opioid overdose deaths. For related discuss ion cl ick here and scrol l  down to highl ighted
heading in bi te’s  Issues section.
G  Scottish Drugs  Forum naloxone web s i te. Offers  resources, advice, guidance, information and news on programmes featuring the
drug naloxone which reverses  opiate overdose. Being reconstructed at time of writing. For related discuss ion cl ick here and scrol l
down to highl ighted heading in bi te’s  Issues section.
G  Best practice in drug misuse interventions  including harm reduction (European Monitoring Centre for Drugs  and Drug Addiction
[EMCDDA], accessed 2017). Web-based guidance from the EU’s  drug pol icy and practice evidence centre, offering several  fact
sheets  related to harm reduction.
MORE  This  search retrieves  a l l  relevant documents .
For sub-topics  go to the subject search page or hot topics  on harm reduction, overdose prevention, naloxone programmes, and
curbing spread of hepati tis  C.
Last revised 03 September 2017. Fi rst uploaded 01 June 2013
 Comment/query to editor
 Suggest a  new document to add to this  cel l
 Return to/go to Drugs  Matrix
 Open Effectiveness  Bank home page
 Add your name to the mai l ing l i s t to be alerted to new studies  and other s i te updates
 Open Matrix Bite guide to this cell . Original bites funded by  Close atrix Bite 
inks to other documents. Hover over for not s. Click to highlight passage referred to. Unfold extra text 
What is this cell about? Reducing the harms experienced by the user as a result of their drug use, without
necessarily reducing use or seeking to overcome dependence. Seemingly a straightforward humanitarian
objective, our hot topic n the issue reveals the complications and the intense controversy over an approach
that seems to imply – and in practice requires – a degree of acceptance of illegal drug use. Fundamental
questions include what and whose harms we accept as legitimate intervention targets.
Among the harms in practice focused on are infectious diseases spread by shared injecting equipment, in
particular HIV – the disease which generated modern-day harm reduction in Britain  illustration – but also
hepatitis B and C, and the prevention of ‘overdose’ fatalities.
Typically, harm is reduced by changing how drugs are used. Common interventions include needle exchanges
which try to ensure that only infection-free injecting equipment is used, and education and skills training to
help users avoid particularly risky practices. Substituting a legally prescribed drug of the same type for the
original (and usually illegally
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original (and usually illegally
obtained) substance often has both
harm reduction and treatment
objectives and effects; research on
these approaches is also to be
found in cell A3. Harm reduction
activities may take place in a
criminal justice context and
services may prioritise preventing
harms to the community rather than
to the drug user, issues addressed
also in cell A5.
The current cell is well stocked
compared to succeeding cells in the row, reflecting the greater research emphasis given to testing
interventions as opposed to the impact of the practitioner delivering them (cell B1), how they and the service
are managed (cell C1), the strengths and ethos of the service-providing organisation (cell D1), and the entire
service network (cell E1). This should not be taken to mean interventions are primary and the other influences
secondary. Systems of interacting services and initiatives synergistically reduce harm to an extent beyond the
reach of any one type of intervention. An example is how methadone maintenance reduces the number of
injections, making it easier for needle exchanges to meet the remaining need for injecting equipment, while
exchanges act as conduit into treatment. Simply providing a harm reduction service is no guarantee it will
reduce harm; how services are run is critical. Examples include high doses in substitute prescribing rather than
a mentality of trying to get to a drug-free state, and liberal dispensing of injecting equipment rather than the
more disciplinarian approach of insisting on the corresponding return of used equipment.
Where should I start? First survey the territory from the vantage point offered by a panoramic review from
a UK perspective, one of a series funded to provide “rigorous, independent” assessments of the effectiveness
of drug policies. Its trio of authors have long experience researching, reviewing and working in the UK drug
sector, including at national policy level, and reinforce the credibility of their conclusions by referral to the
findings and recommendations of agencies of the United Nations. They lay out the intervention options
(needle exchange, drug consumption rooms, methadone and heroin prescribing, media campaigns, outreach
and psychosocial interventions) to reduce harms specifically to health (viral and bacterial infections and
overdose), consider each of the harms and interventions in turn, specifically address harm reduction in prisons,
and consider the main challenges to implementation, prominent among which is “ideological unease at being
‘soft’ on drug users”.
The World Health Organization’s strong recommendation in 2014 that “People likely to witness an opioid
overdose should have access to naloxone and be instructed in its administration” is the main development the
review would have been sure to include; otherwise evidence has accumulated but the policy and practice
implications have not changed much since its publication in 2005. 
Highlighted study Ironically, one of the European nations most resistant to prescribing heroin-type drugs to
dependent heroin users has for that reason been able to most convincingly demonstrate its value. Restrictions
on methadone maintenance in Sweden made it possible to allow or deny this treatment effectively at random.
In states such as the UK, where patients can readily choose to start
treatment, their progress compared to drug users not on methadone
might be due to pre-existing differences rather than the treatment
itself. Swedish restrictions levelled the playing field between
methadone and other approaches to a degree not possible where
methadone was readily available.
The single most important study tracked patients admitted to Sweden’s national methadone programme before
a five-year ban on enrolling new patients. Their fate was compared to that of addicts eligible for the
programme, but who did not get in before the ban or had randomly been denied entry. All this comparison
group availed themselves of Sweden’s well developed detoxification and drug-free treatment services, yet over
on average the next six years, 4 in 10 had died. Over about the same period, only around 1 in 8 of the
methadone patients had died. Overwhelmingly, opiate overdose was the main reason for the difference.
This seminal and still highly significant study was followed by others with the same implications. Published in
2009, another Swedish study found that the annual death rate was 1% while patients were on methadone but
2% among untreated opiate misusers. During an enforced break in treatment, hospital admissions rose only to
fall again when the same patients were allowed to return, strong evidence that treatment was an active
ingredient in avoiding illness and death. In 2010 a further study showed what Sweden could have done had it
expanded its maintenance programmes more widely and sooner. It found that a major expansion in provision
and easing of restrictions between 2000 and 2006 were associated with and may have contributed to declines
in opiate-related deaths and hospitalisations  chart.
The same message has come from neighbouring Norway, which also has restricted access to methadone.
There a study traded on the typically five or six months patients had to wait before they could get a slot at a
clinic. All the study’s participants had applied for and
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clinic. All the study’s participants had applied for and
been assessed as qualifying for this treatment, yet
many were forced to wait, enabling researchers to
assess the impact of being denied immediate treatment,
itself a guide to what might have happened to all the
opiate users had there been no treatment to wait for.
Compared to immediate treatment, the results implied
that for each 100 people made to wait for maintenance,
an extra one or two will die per year. In line with other
studies, the bounce back to pre-treatment overdose
death rates after leaving treatment supports a view of
methadone and other substitute prescribing
programmes as an on-off switch. People in need of this
treatment generally quickly improve when it is ‘switched
on’, but rapidly relapse once it is off, and especially if it
is switched off against the patient’s wishes. Despite this, over the span of the study in-treatment gains
overshadowed post-treatment reverses, leaving a substantial net benefit.
Also in Norway, the rebound effect emerged in another study. Even when some illegal drug use continued,
being in methadone or buprenorphine treatment dramatically cut hospital admissions due to drug-related
physical complaints, but these rebounded when patients left, often forced out due to ongoing drugtaking,
opposition to programme rules and controls, or instability in taking their medication.
Given the lack of randomised trials – now impossible due to proof that denying substitute prescribing will lead
to avoidable deaths – the Scandinavian evidence is the best we have. But there is at least one randomised trial
with similar implications. From the USA, it showed that continued maintenance curbs risk of infection and
sustains reductions in illicit opioid use more effectively than gradual detoxification, even if during and after
that patients are well supported.
Issues to consider and discuss
 What would have happened if we’d been told the whole story about pilot needle
exchanges in Britain? To test this then controversial anti-HIV strategy, in 1987 the UK government
commissioned an investigation of 15 pilot needle exchanges. Two years later a report in the journal AIDS
announced “small but encouraging” reductions in the HIV risk behaviour of exchange attendees versus other
injectors who had not attended exchanges – enough to legitimate nationwide expansion. However, the study
as a whole, and especially its public presentation in the journal, were seriously flawed. Had the whole truth
been revealed, the UK might not have developed the widespread needle exchange provision commonly
credited with avoiding HIV epidemics seen elsewhere.
What was the problem? Turn to our analysis for the detailed story. In brief, the pilot exchanges neither
attracted high-risk injectors nor could it be shown they reduced risk. Unexpectedly, few injectors who tried the
exchanges repeatedly returned, meaning very few were recruited to the study and followed up. The impression
that they had reduced their risk more than non-attendees was based on a tiny proportion of exchange users,
and on a benchmarking comparison group (numbered 2 in the figure above) which in fact was not comparable
at all.
Omitted from the journal article was another, more appropriate comparison group (numbered 1 in the figure)
of non-attendees. Like the attendees, they were the same people re-interviewed three months later, not a
different set of injectors freshly recruited. Without ever attending
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different set of injectors freshly recruited. Without ever attending
a needle exchange, they had actually reduced their risk behaviour
more than the exchange users – a result which jeopardised the
continuance of needle exchange provision.
Both comparisons were there in (at that time) typewritten black
and white in the technical research report, but the published journal article referred only to the more
encouraging comparison, and seemed to flatly deny the existence of the one which suggested exchanges were
counterproductive. A mistake, a misunderstanding, or an example of the well known ‘researcher allegiance
effect’ – the tendency for researchers committed to an intervention to report good results?
In retrospect, it is no surprise that the pilots failed to attract and retain or influence their generally fleeting
attendees. Our series on hepatitis C and needle exchange cited the observation that exchanges often choose
to or are forced to operate under “restrictions that condemn the programmes to fall far short of the needs of
the persons for whom they were designed”. By under-resourcing and underdervaluing this work and forcing
exchanges to operate under crippling restrictions, sceptical authorities create the conditions which justify their
misgivings. Click to  unfold the supplementary text, and you will see there was more than a hint of that in
the restrictions placed on the pilot exchanges.
If not intentionally set up to fail, the 15 pilot schemes faced restrictions and conditions which would probably,
and in some cases, inevitably, lead to this result – one reflected in the bottom-line finding of the evaluation
obscured from public view.
Whatever the reason for that omission, the effect was arguably beneficial. Many people are alive and disease-
free today who would not have been had the exchange strategy been abandoned. We now know enough to be
confident that despite its findings, exchanges run on the right lines can help curb disease spread. Where do
you stand on this issue? Should the evaluation results have been fully reported, even if that might have meant
the end of needle exchange in Britain? As elsewhere, it might have been a case of needle exchange’s doubters
creating a self-fulfilling prophecy by shackling and under-resourcing the facilities.
 Has methadone maintenance intercepted the spread of hepatitis C? For decades (see for
example a seminal US study) we have known that methadone maintenance can reduce transmission of the HIV
virus. In respect of hepatitis C, the consensus has been quite different, but seems recently to have changed.
In 2003 we explained that what made this virus so much harder to contain than HIV was “the degree of
behaviour change needed to intercept its transmission. Reductions in risky sharing of injecting equipment can
be enough to minimise the spread of HIV. For hepatitis C, the emphasis is less on reduction, more on
elimination … The challenge posed by the virus arises from a combination of robustness, infectivity and
prevalence.”
“Prevalence” refers to the critical fact that “the virus took hold before anyone knew it existed and well before
anti-infection measures were implemented in response to HIV”. Before in 1989 a diagnostic test was
available, it had already infected a much larger fraction of drug injectors than HIV ever would, making it more
difficult to achieve the same proportionate reduction than if the starting point had been lower. Since then it
has been a case of playing catch-up against a rapidly moving target.
Against this background, over 2003 and 2004 our series on hepatitis C focused on needle exchange because
methadone maintenance – the only other drug service to attract large numbers of injectors – “has a convincing
record on HIV but has yet to be shown to significantly curb hepatitis C. Usually it is entered too late to prevent
most patients already being infected and has at best only a moderate impact on risk behaviour.”
Recent studies – not least in the UK – have forced that generally accepted dismissal of substitute prescribing
to be reconsidered. By 2011 the evidence had tilted towards substitute prescribing, but remained too
insubstantial and inconsistent to be relied on. Nevertheless, findings from the eight studies gathered together
then in a review cumulated to the near-significant estimate that the chances of injectors who received opioid
substitution treatment becoming infected were 40% less than those of comparison injectors. That this might
not have been an artefact of more harm-reduction oriented injectors choosing to enter treatment was
indicated by the fact that other types of treatment were not associated a similar reduction. An important
harbinger of later findings was that staying in substitute prescribing seemed more effective than having been
in and left, or going in and out of the treatment.
By 2014 later studies not included in the review were seen by a quartet of influential researchers from Britain,
Australia and the USA as having decisively tipped the balance in favour of substitute prescribing. Their
unqualified conclusion was that opioid substitution treatment “averts infections” with hepatitis C. They also
felt it “may also have an accumulating effect – the longer the average duration … the greater the impact on
reducing [hepatitis C] risk and drug related mortality”.
Listed above and among the studies they cited was a synthesis of
results from UK studies. Published in 2011, it estimated that when
injectors were engaged in substitute prescribing for at least half of a
12-month follow-up period, the chances of their becoming infected
with hepatitis C were less than half those of other injectors –
substantial, but still not a statistically significant difference. The
following year this data was fed into a simulation model which suggested that current high coverage levels of
opioid substitute prescribing may have contributed to reducing chronic hepatitis C prevalence from 57% to
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opioid substitute prescribing may have contributed to reducing chronic hepatitis C prevalence from 57% to
40%. Risk of transmission was lowest if opioid injectors engaged in both high-coverage needle exchange and
substitute prescribing, but engaging in just substitute prescribing was estimated to reduce this risk by half –
again substantial, but still not a finding which could confidently be declared to represent a result not due
simply to chance. Unfold  the supplementary text for more on the studies which by 2014 had led to the
conclusion that opioid substitute treatment can help prevent the spread of hepatitis C.
Some of the apparent infection reductions found in these studies were very large, but with ethical and
practical considerations prohibiting the randomised denial of substitute prescribing, the results might have
been due to influences other than treatment. Studies do their best to compensate for known influences, but
cannot compensate for those not measured. Set against this is the common finding that treatments other than
substitute prescribing are not (or not to the same degree) associated with a reduced chance of becoming
infected with hepatitis C; if entering treatment was a marker of a pre-existing tendency to avoid infection, it
should apply to all treatments, yet only substitute prescribing has developed a consistent record. Despite the
difficulties, the evidence was enough to convince European Union and UN authorities that substitute
prescribing should be a major component of anti-infection policies.
How convinced are you? Have we late in the day come to realise that the typically imperfect drug use
reductions generated by maintenance prescribing are enough to slow the spread even of hepatitis C? Or is the
evidence still too circumstantial? If maintenance prescribing was required to meet the same criteria as a new
cancer treatment, would ‘associations’ be enough without the reassurance of randomised trials to establish
causality? Or do we have accept that such trials have become impossible, so we must act on the basis of less
conclusive evidence or risk avoidable infections and deaths among drug injectors? Note that we do have at
least one randomised trial which showed that continued methadone maintenance reduces behaviour risking
infection more effectively than gradual detoxification, even if during and after that patients are well
supported.
 How much of a difference has naloxone made? Naloxone is a drug which specifically targets
overdoses involving opiate-type drugs – still by far the major contributors to the deaths – rapidly reversing
their effects, including the respiratory depression which causes overdose. Worrying increases in overdose
deaths between 2013 and 2015 in every nation in the United Kingdom – which got even worse the following
year (1 2) – focused attention on programmes to distribute the drug and train drug users and others to how to
use it, but also raise fears that these programmes are not yet having the intended impacts. If there is s litmus
test in the UK, it is the performance of the determined national naloxone campaign in Scotland, examined
below.
Detailed in our hot topic on the issue, providing naloxone became the main new hope for curbing the death
rate after in 2005 UK law was amended to permit emergency
administration by any member of the public, and further relaxed in
2015 to permit drug services in England and Wales without
prescription to order supplies and distribute these to drug users at
risk of overdose or to people likely to be in contact with them, such
as families, carers or hostel staff.
As an intervention, widespread training of potential onlookers to administer naloxone in case of overdose
seems close to a sure-fire solution to this leading cause of sudden death among drug users, but as often the
case, implementation rather than efficacy is the weak link. The most determined implementation drive in the
UK has been in Scotland. Launched in 2011, in 2015/16 7214 kits had been issued in the community and 932 to
prisoners about to be released. Whether this programme had the intended effects will influence developments
across the UK.
An extremely high-risk period for former opiate users, in Scotland the proportion of opioid-related deaths
occurring within four weeks of release from prison had been identified as the key indicator of success of a
programme which had specifically and systematically targeted prisons. This was made the main metric in a
study listed above which compared opioid-related death rates in the five years before the programme’s
implementation (2006–10) with those during its first three years (2011–13). A secondary indicator of success
added in the proportion which occurred during the corresponding period after discharge from hospital, another
high-risk period.
The post-prison period accounted for 9.8% of opioid-related deaths before the programme but 6.3% after – a
36% reduction taken as indicative of a lifesaving impact  chart. Also reduced was the combined total of post-
prison and post-hospital deaths as a proportion of the total. Routinely collected statistics indicated that the
trend down in the proportion of opioid-related deaths occurring shortly after release from prison continued into
2014, when the figure was 3.1%, having steadily decreased since the start of the national naloxone
programme.
However, trends in deaths after release from hospital gave no corresponding indication that the programme
had helped. Together with the increase in total opioid-related deaths between 2014 and 2016, it calls into
question whether overall the programme has had the desired effects, even if it further reduced the small
minority of deaths which occur after release from prison.
Reliance on post-prison opioid-related deaths to demonstrate the programme’s success in turn relies on
evidence that the systematic targeting of prisons to issue kits actually worked, and produced more complete
and/or higher quality implementation than outside
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As the number of naloxone kits issued in
prison increased, post-prison deaths
accounted for a diminishing % of all opioid-
related deaths in Scotland.
and/or higher quality implementation than outside
prisons, accounting for the reduced proportion of deaths
occurring on release. Read our analysis and see if you
agree that this proposition is questionable, and with it the
decision to use the proportion of opioid-related deaths
occurring after prison release as the main yardstick of the
programme’s success.
It is implausible that such widespread distribution of
naloxone and training for its administration did not save
lives. The difficulty is in proving this against a background
of what is presumed to be upward pressure on the deaths
total due to the aging of the heroin-using population.
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